Two non-peptide CRF1 receptor antagonists (DMP696, DMP904) showed anxiolytic activity with distinct pharmacological profiles, advancing the CRF1 antagonist drug class for anxiety and depression treatment.
Key findingDMP696 and DMP904 demonstrated CRF1 receptor antagonist anxiolytic activity with distinct pharmacokinetic, selectivity, and efficacy profiles across a
What the researchers found
DMP696 and DMP904 demonstrated CRF1 receptor antagonist anxiolytic activity with distinct pharmacokinetic, selectivity, and efficacy profiles across anxiety models — advancing multiple CRF1 drug candidates with different clinical potential.
Why it matters
Relevant for neuropeptides, anxiety-mood.
How the study worked
review study on neuropeptides, anxiety-mood.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2005.
The bigger picture
Advances peptide research with clinical implications.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists.
CNS drug reviews, 11(1), 21-52
Citation
Li, Yu-Wen; Fitzgerald, Lawrence; Wong, Harvey; Lelas, Snjezana; Zhang, Ge; Lindner, Mark D; Wallace, Tanya; McElroy, John; Lodge, Nicholas J; Gilligan, Paul; Zaczek, Robert. (2005). The pharmacology of DMP696 and DMP904, non-peptidergic CRF1 receptor antagonists.. CNS drug reviews, 11(1), 21-52.